Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.38 |
| ▸ | MMP8 | P22894 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5963652 | 1.00 | LAP3 (0.39) | LAP3TDP1ALDH1A1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL3211434 | 1.00 | LAP3 (0.39) | LAP3TDP1ALDH1A1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL3215377 | 1.00 | LAP3 (0.39) | LAP3TDP1ALDH1A1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL3232688 | 1.00 | LAP3 (0.39) | LAP3TDP1ALDH1A1PGK1PGK2 | |
| Pyrophosphoric Acid SCHEMBL28225126 | 0.83 | BLM (0.53) | LAP3TDP1PGK1PGK2BTN3A1 | |
| SCHEMBL23621 | 0.82 | — | — | |
| SCHEMBL1667694 | 0.82 | — | — | |
| Phosphoric Acid SCHEMBL14993414 | 0.80 | LAP3 (0.39) | LAP3TDP1ALDH1A1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL5963882 | 0.79 | BTN3A1 (0.43) | LAP3PGK1PGK2BTN3A1MMP1 | |
| Phosphoric Acid SCHEMBL22235268 | 0.78 | CA2 (0.46) | LAP3TDP1ALDH1A1PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068179-A1 | Phosphohalohydrins, Process For The Production Thereof And Use Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2010-03-18 | — | — | US | disclosed |
| US-7625879-B2 | Phosphohalohydrins, process for the production thereof and use thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2009-12-01 | — | — | US | disclosed |
| US-7432253-B2 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20060287274-A1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2006-12-21 | — | — | US | disclosed |
| US-20060287281-A1 | Phosphohalohydrins, process for the production thereof and use thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2006-12-21 | — | — | US | disclosed |
| US-7109183-B2 | Phosphohalohydrins, process for the production thereof and use thereof | Institut National de la Sante et de la Recherchik Medicale (FR) | 2006-09-19 | — | — | US | disclosed |
| US-7101711-B1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (FR) | 2006-09-05 | — | — | US | disclosed |
| US-20040087555-A1 | Phosphohalohydrins, process for the production thereof and use thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICATE (FR) | 2004-05-06 | — | — | US | disclosed |
| US-6660723-B1 | Activating primate gamma delta lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2003-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287274-A1 | Phosphoepoxides, method for making same and uses | CD4, CCR9, BCL9 | LAP3 3801/4885TDP1 1768/4885ALDH1A1 1720/4885 |
| US-20040087555-A1 | Phosphohalohydrins, process for the production thereof and use thereof | CD4, HRH3, HRH1 | LAP3 2100/4885TDP1 1064/4885ALDH1A1 3603/4885 |
| US-20060287281-A1 | Phosphohalohydrins, process for the production thereof and use thereof | CD4, CCR9, BCL9 | LAP3 3613/4885TDP1 2256/4885ALDH1A1 2542/4885 |
| US-20100068179-A1 | Phosphohalohydrins, Process For The Production Thereof And Use Thereof | CD4, CCR9, ICOS | LAP3 3476/4885TDP1 2882/4885ALDH1A1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.